BOLD Stock Forecast: Boundless Bio, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Boundless Bio, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Boundless Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Value (34): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BOLD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BOLD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $4.00 |
| 2 June 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 28 May 2025 | Leerink Partners | Downgrade | Market Perform | — |
| 13 Dec 2024 | Guggenheim | Downgrade | Neutral | — |
| 22 Apr 2024 | Guggenheim | Initiates | Buy | — |
| 22 Apr 2024 | Leerink Partners | Initiates | Outperform | — |
| 22 Apr 2024 | Piper Sandler | Initiates | Overweight | — |
| 9 Dec 2019 | Evercore ISI Group | Downgrade | In-Line | — |
| 6 Dec 2019 | JP Morgan | Downgrade | Neutral | — |
| 4 Dec 2019 | Chardan Capital | Downgrade | Neutral | $60 |
| 4 Dec 2019 | SVB Leerink | Downgrade | Market Perform | — |
| 3 Dec 2019 | Baird | Upgrade | Neutral | — |
| 3 Dec 2019 | BMO Capital | Downgrade | Market Perform | $47 → $60 |
| 3 Dec 2019 | Citigroup | Upgrade | Neutral | $30 → $60 |
| 3 Dec 2019 | Guggenheim | Downgrade | Neutral | — |
| 3 Dec 2019 | HC Wainwright & Co. | Downgrade | Neutral | $60 |
| 3 Dec 2019 | Piper Jaffray | Downgrade | Neutral | — |
| 3 Dec 2019 | Piper Sandler | Downgrade | Neutral | $55 → $60 |
| 3 Dec 2019 | Raymond James | Downgrade | Market Perform | — |
| 3 Dec 2019 | Wedbush | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BOLD.
This page is one stock. Monday covers all of them.
BOLD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BOLD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Boundless Bio, Inc. returned +109.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BOLD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −64.6%
- Return on assets
- −31.2%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Boundless Bio, Inc. has a market value of $54.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$64.0M.
Diluted earnings per share, trailing twelve months: −$2.86.
Free cash flow in the twelve months to 30 June 2026: −$56.7M.
Boundless Bio, Inc. employs 28 people.
Data provided by Twelve Data
BOLD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BOLD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Boundless Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BOLD
What is the BOLD stock price forecast for 2026-2027?
The median 12-month analyst price target for Boundless Bio, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BOLD stock a buy right now?
Of the 1 analyst covering Boundless Bio, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Boundless Bio, Inc. 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BOLD?
As at 21 Nov 2026, Boundless Bio, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
Will BOLD stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $4, and Ticker Nerd's factor model ranks Boundless Bio, Inc. 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BOLD stock forecast for 2030?
No analyst covering Boundless Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BOLD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has BOLD stock performed over the past year?
Boundless Bio, Inc. returned +109.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Boundless Bio, Inc. do?
Boundless Bio Inc. is a clinical-stage oncology company focused on developing precision cancer therapies for tumors driven by oncogene amplification. Its work centers on extrachromosomal DNA (ecDNA), a biological mechanism that can fuel cancer growth, adaptation, and resistance to existing treatments.
About Boundless Bio, Inc.
Boundless Bio Inc. is a clinical-stage oncology company focused on developing precision cancer therapies for tumors driven by oncogene amplification. Its work centers on extrachromosomal DNA (ecDNA), a biological mechanism that can fuel cancer growth, adaptation, and resistance to existing treatments. Using its proprietary Spyglass platform, Boundless Bio identifies ecDNA-related targets and designs ecDNA-directed therapeutic candidates intended to disrupt the pathways cancer cells use to survive. The company’s current pipeline includes oral small-molecule programs such as BBI-940 and other ecDNA-directed therapies being evaluated in clinical studies across hard-to-treat cancer types. Boundless Bio Inc. operates in the biotechnology sector and serves the broader oncology market with a research-driven approach aimed at addressing unmet needs in patients with oncogene-amplified cancers.
CEO Mr. Zachary D. Hornby · 28 employees · United States · https://boundlessbio.com